{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T20:05:30Z","timestamp":1769630730429,"version":"3.49.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,18]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Novel-fosfamides (NFOs) belong to active metabolites of ifosfamide that bypass the generation of toxic byproducts. In this analysis, we aimed to comprehensively assess the benefits and risks of NFO monotherapy or in combination with doxorubicin (DOX) versus single-drug DOX in previously untreated patients with advanced soft-tissue sarcoma (ASTS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Online PubMed, Web of Science, Embase, and Cochrane CENTRAL databases were systematically searched on April 26, 2022. Objective response rate and disease control rate were primary outcomes. Overall survival (OS), progression-free survival (PFS), and grade \u2265 3 treatment-related adverse events were secondary outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In all, 3 randomized clinical trials with a total of 1207 ASTS patients were eligible. DOX plus NFO combination therapy showed higher risk ratios of objective response rate (1.50, 95% CI 1.20\u20131.68, <jats:italic toggle=\"yes\">P<\/jats:italic> = .0003) and disease control rate (1.15, 95% CI 1.05\u20131.27, <jats:italic toggle=\"yes\">P<\/jats:italic> = .0030) compared with DOX monotherapy. Nevertheless, NFO-based monotherapy and combination therapy were found no improvements on OS (hazard ratio 0.93, 95% CI 0.52\u20131.65, <jats:italic toggle=\"yes\">P<\/jats:italic> = .8050) and PFS (hazard ratio 0.88, 95% CI 0.54\u20131.43, <jats:italic toggle=\"yes\">P<\/jats:italic> = .6088) against DOX. More incidences of grade 3 or worse anemia, thrombocytopenia, stomatitis, diarrhea, constipation, and febrile neutropenia were observed in NFO-based treatments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Adding NFO to DOX as first-line therapy improved the responses in ASTS patients but did not prolong OS and PFS. Grade 3 or worse treatment-related adverse events should be treated with caution during the NFO-based therapies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000034902","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T17:04:54Z","timestamp":1692637494000},"page":"e34902","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Novel-fosfamide monotherapy or in combination with doxorubicin versus doxorubicin alone in patients with advanced soft tissue sarcoma: A pooled analysis of randomized clinical trials"],"prefix":"10.1097","volume":"102","author":[{"given":"Xin-Xiu","family":"Liu","sequence":"first","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Hong","family":"Han","sequence":"additional","affiliation":[{"name":"Nursing Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-Hua","family":"Kuang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-He","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4598-7721","authenticated-orcid":false,"given":"Bi-Cheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/PAP.0000000000000284","article-title":"The 2020 WHO classification of tumors of soft tissue: selected changes and new entities.","volume":"28","author":"Choi","year":"2021","journal-title":"Adv Anat Pathol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.6004\/jnccn.2020.0058","article-title":"NCCN guidelines insights: soft tissue sarcoma, version 1.2021.","volume":"18","author":"von Mehren","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1200\/JCO.1995.13.7.1537","article-title":"Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first- line treatment of advanced soft tissue sarcomas: a randomized study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group.","volume":"13","author":"Santoro","year":"1995","journal-title":"J Clin Oncol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1200\/JCO.2008.19.2930","article-title":"Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.","volume":"27","author":"Maurel","year":"2009","journal-title":"J Clin Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"762288","DOI":"10.3389\/fonc.2021.762288","article-title":"Doxorubicin\/adriamycin monotherapy or plus ifosfamide in first-line treatment for advanced soft tissue sarcoma: a pooled analysis of randomized trials.","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1634\/theoncologist.12-11-1351","article-title":"The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.","volume":"12","author":"Tascilar","year":"2007","journal-title":"Oncologist"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00280-008-0922-4","article-title":"Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma.","volume":"64","author":"Hingorani","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"R10-20250504","first-page":"e123","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.","volume":"3","author":"Moher","year":"2009","journal-title":"Open Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis.","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2016.67.6684","article-title":"PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma.","volume":"34","author":"Ryan","year":"2016","journal-title":"J Clin Oncol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S1470-2045(17)30381-9","article-title":"Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406\/SARC021): an international, multicentre, open-label, randomised phase 3 trial.","volume":"18","author":"Tap","year":"2017","journal-title":"Lancet Oncol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejca.2019.10.016","article-title":"Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma.","volume":"124","author":"Hartmann","year":"2020","journal-title":"Eur J Cancer"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.amjsurg.2020.11.041","article-title":"The importance of the margin of resection and radiotherapy in retroperitoneal liposarcoma.","volume":"221","author":"Littau","year":"2021","journal-title":"Am J Surg"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12885-022-09176-1","article-title":"Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study.","volume":"22","author":"Tian","year":"2022","journal-title":"BMC Cancer"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"e001580","DOI":"10.1136\/jitc-2020-001580","article-title":"Immunotherapy for sarcomas: new frontiers and unveiled opportunities.","volume":"9","author":"Birdi","year":"2021","journal-title":"J ImmunoTher Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:07:06Z","timestamp":1746320826000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":17,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034902","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,18]]}}}